Development and validation of a prognostic model to predict relapse in adults with remitted depression in primary care: secondary analysis of pooled individual participant data from multiple studies.


Journal

BMJ mental health
ISSN: 2755-9734
Titre abrégé: BMJ Ment Health
Pays: England
ID NLM: 9918521385306676

Informations de publication

Date de publication:
28 Oct 2024
Historique:
received: 27 06 2024
accepted: 09 10 2024
medline: 29 10 2024
pubmed: 29 10 2024
entrez: 28 10 2024
Statut: epublish

Résumé

Relapse of depression is common and contributes to the overall associated morbidity and burden. We lack evidence-based tools to estimate an individual's risk of relapse after treatment in primary care, which may help us more effectively target relapse prevention. The objective was to develop and validate a prognostic model to predict risk of relapse of depression in primary care. Multilevel logistic regression models were developed, using individual participant data from seven primary care-based studies (n=1244), to predict relapse of depression. The model was internally validated using bootstrapping, and generalisability was explored using internal-external cross-validation. Residual depressive symptoms (OR: 1.13 (95% CI: 1.07 to 1.20), p<0.001) and baseline depression severity (OR: 1.07 (1.04 to 1.11), p<0.001) were associated with relapse. The validated model had low discrimination (C-statistic 0.60 (0.55-0.65)) and miscalibration concerns (calibration slope 0.81 (0.31-1.31)). On secondary analysis, being in a relationship was associated with reduced risk of relapse (OR: 0.43 (0.28-0.67), p<0.001); this remained statistically significant after correction for multiple significance testing. We could not predict risk of depression relapse with sufficient accuracy in primary care data, using routinely recorded measures. Relationship status warrants further research to explore its role as a prognostic factor for relapse. Until we can accurately stratify patients according to risk of relapse, a universal approach to relapse prevention may be most beneficial, either during acute-phase treatment or post remission. Where possible, this could be guided by the presence or absence of known prognostic factors (eg, residual depressive symptoms) and targeted towards these. NCT04666662.

Sections du résumé

BACKGROUND BACKGROUND
Relapse of depression is common and contributes to the overall associated morbidity and burden. We lack evidence-based tools to estimate an individual's risk of relapse after treatment in primary care, which may help us more effectively target relapse prevention.
OBJECTIVE OBJECTIVE
The objective was to develop and validate a prognostic model to predict risk of relapse of depression in primary care.
METHODS METHODS
Multilevel logistic regression models were developed, using individual participant data from seven primary care-based studies (n=1244), to predict relapse of depression. The model was internally validated using bootstrapping, and generalisability was explored using internal-external cross-validation.
FINDINGS RESULTS
Residual depressive symptoms (OR: 1.13 (95% CI: 1.07 to 1.20), p<0.001) and baseline depression severity (OR: 1.07 (1.04 to 1.11), p<0.001) were associated with relapse. The validated model had low discrimination (C-statistic 0.60 (0.55-0.65)) and miscalibration concerns (calibration slope 0.81 (0.31-1.31)). On secondary analysis, being in a relationship was associated with reduced risk of relapse (OR: 0.43 (0.28-0.67), p<0.001); this remained statistically significant after correction for multiple significance testing.
CONCLUSIONS CONCLUSIONS
We could not predict risk of depression relapse with sufficient accuracy in primary care data, using routinely recorded measures. Relationship status warrants further research to explore its role as a prognostic factor for relapse.
CLINICAL IMPLICATIONS CONCLUSIONS
Until we can accurately stratify patients according to risk of relapse, a universal approach to relapse prevention may be most beneficial, either during acute-phase treatment or post remission. Where possible, this could be guided by the presence or absence of known prognostic factors (eg, residual depressive symptoms) and targeted towards these.
TRIAL REGISTRATION NUMBER BACKGROUND
NCT04666662.

Identifiants

pubmed: 39467616
pii: bmjment-2024-301226
doi: 10.1136/bmjment-2024-301226
pii:
doi:

Banques de données

ClinicalTrials.gov
['NCT04666662']

Types de publication

Journal Article Validation Study

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Auteurs

Andrew S Moriarty (AS)

Hull York Medical School and Department of Health Sciences, University of York, York, Yorkshire, UK andrew.moriarty@york.ac.uk.

Lewis W Paton (LW)

Hull York Medical School and Department of Health Sciences, University of York, York, Yorkshire, UK.

Kym I E Snell (KIE)

Institute of Applied Health Research, University of Birmingham, Birmingham, UK.

Lucinda Archer (L)

Institute of Applied Health Research, University of Birmingham, Birmingham, UK.

Richard D Riley (RD)

Institute of Applied Health Research, University of Birmingham, Birmingham, UK.

Joshua E J Buckman (JEJ)

Research Department of Clinical, Educational and Health Psychology, University College London, London, UK.
iCope-Camden and Islington Psychological Therapies Services, Camden and Islington NHS Foundation Trust, London, UK.

Carolyn A Chew Graham (CA)

School of Medicine, Keele University, Keele, Staffordshire, UK.

Simon Gilbody (S)

Hull York Medical School and Department of Health Sciences, University of York, York, UK.

Shehzad Ali (S)

Schulich School of Medicine & Dentistry, Western University, London, Great Britain, Canada.

Stephen Pilling (S)

Research Department of Clinical, Educational and Health Psychology, University College London, London, UK.
Camden and Islington NHS Foundation Trust, London, UK.

Nick Meader (N)

Population Health Sciences Institute, University of Newcastle upon Tyne, Newcastle upon Tyne, UK.

Bob Phillips (B)

Hull York Medical School, University of York, York, Yorkshire, UK.

Peter A Coventry (PA)

Department of Health Sciences, University of York, York, Yorkshire, UK.

Jaime Delgadillo (J)

Department of Psychology, The University of Sheffield, Sheffield, UK.

David A Richards (DA)

Faculty of Health and Life Sciences, University of Exeter, Exeter, UK.
Department of Health and Caring Sciences, Western Norway University of Applied Sciences, Bergen, Hordaland, Norway.

Chris Salisbury (C)

Centre for Academic Primary Care, University of Bristol, Bristol, UK.

Dean McMillan (D)

Hull York Medical School and Department of Health Sciences, University of York, York, Yorkshire, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH